This article provides an update on the global cancer burden using the GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer. Worldwide, an estimated 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and almost 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) occurred in 2020. Female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases (11.7%), followed by lung (11.4%), colorectal (10.0 %), prostate (7.3%), and stomach (5.6%) cancers. Lung cancer remained the leading cause of cancer death, with an estimated 1.8 million deaths (18%), followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%) cancers. Overall incidence was from 2-fold to 3-fold higher in transitioned versus transitioning countries for both sexes, whereas mortality varied <2-fold for men and little for women. Death rates for female breast and cervical cancers, however, were considerably higher in transitioning versus transitioned countries (15.0 vs 12.8 per 100,000 and 12.4 vs 5.2 per 100,000, respectively). The global cancer burden is expected to be 28.4 million cases in 2040, a 47% rise from 2020, with a larger increase in transitioning (64% to 95%) versus transitioned (32% to 56%) countries due to demographic changes, although this may be further exacerbated by increasing risk factors associated with globalization and a growing economy. Efforts to build a sustainable infrastructure for the dissemination of cancer prevention measures and provision of cancer care in transitioning countries is critical for global cancer control.

https://acsjournals.onlinelibrary.wiley.com/doi/pdf/10.3322/caac.21660

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

With increasing incidence and mortality, cancer is the leading cause of death in China and is a major public health problem. Because of China's massive population (1.37 billion), previous national incidence and mortality estimates have been limited to small samples of the population using data from the 1990s or based on a specific year. With high-quality data from an additional number of population-based registries now available through the National Central Cancer Registry of China, the authors analyzed data from 72 local, population-based cancer registries (2009-2011), representing 6.5% of the population, to estimate the number of new cases and cancer deaths for 2015. Data from 22 registries were used for trend analyses (2000-2011). The results indicated that an estimated 4292,000 new cancer cases and 2814,000 cancer deaths would occur in China in 2015, with lung cancer being the most common incident cancer and the leading cause of cancer death. Stomach, esophageal, and liver cancers were also commonly diagnosed and were identified as leading causes of cancer death. Residents of rural areas had significantly higher age-standardized (Segi population) incidence and mortality rates for all cancers combined than urban residents (213.6 per 100,000 vs 191.5 per 100,000 for incidence; 149.0 per 100,000 vs 109.5 per 100,000 for mortality, respectively). For all cancers combined, the incidence rates were stable during 2000 through 2011 for males (+0.2% per year; P = .1), whereas they increased significantly (+2.2% per year; P < .05) among females. In contrast, the mortality rates since 2006 have decreased significantly for both males (-1.4% per year; P < .05) and females (-1.1% per year; P < .05). Many of the estimated cancer cases and deaths can be prevented through reducing the prevalence of risk factors, while increasing the effectiveness of clinical care delivery, particularly for those living in rural areas and in disadvantaged populations.

https://researchpubs.cancercouncil.com.au/cancercounciljspui/bitstream/1/1728/1/caac21338.pdf

Cancer statistics in China, 2015

Summary Background Since December, 2019, Wuhan, China, has experienced an outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Epidemiological and clinical characteristics of patients with COVID-19 have been reported but risk factors for mortality and a detailed clinical course of illness, including viral shedding, have not been well described. Methods In this retrospective, multicentre cohort study, we included all adult inpatients (≥18 years old) with laboratory-confirmed COVID-19 from Jinyintan Hospital and Wuhan Pulmonary Hospital (Wuhan, China) who had been discharged or had died by Jan 31, 2020. Demographic, clinical, treatment, and laboratory data, including serial samples for viral RNA detection, were extracted from electronic medical records and compared between survivors and non-survivors. We used univariable and multivariable logistic regression methods to explore the risk factors associated with in-hospital death. Findings 191 patients (135 from Jinyintan Hospital and 56 from Wuhan Pulmonary Hospital) were included in this study, of whom 137 were discharged and 54 died in hospital. 91 (48%) patients had a comorbidity, with hypertension being the most common (58 [30%] patients), followed by diabetes (36 [19%] patients) and coronary heart disease (15 [8%] patients). Multivariable regression showed increasing odds of in-hospital death associated with older age (odds ratio 1·10, 95% CI 1·03–1·17, per year increase; p=0·0043), higher Sequential Organ Failure Assessment (SOFA) score (5·65, 2·61–12·23; p Interpretation The potential risk factors of older age, high SOFA score, and d-dimer greater than 1 μg/mL could help clinicians to identify patients with poor prognosis at an early stage. Prolonged viral shedding provides the rationale for a strategy of isolation of infected patients and optimal antiviral interventions in the future. Funding Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences; National Science Grant for Distinguished Young Scholars; National Key Research and Development Program of China; The Beijing Science and Technology Project; and Major Projects of National Science and Technology on New Drug Creation and Development.

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(17)33326-3.pdf

Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines

To the Editor, We have read with interest the manuscript “Discussing sexuality in cancer care: towards personalized information for cancer patients and survivors” by Albers et al. [1]. In a cross-sectional survey among members of cancer patient organizations, the authors investigated the patients’ need for information about sexuality and how to improve communication and aimed to identify “who really wants to know.” The authors concluded that 65% of members had a need for information regarding sexuality. Younger patients, patients with a self-reported negative effect of cancer on sexuality, and patients who were diagnosed less than 2 years ago reported a greater need for information. Most participants were treated for solid cancers. Although we applaud Albers’ work, we believe that we should address the needs of the patients’ partners as well; therefore, we performed a multicenter longitudinal survey to measure the need for information not only among patients with hematological malignancies (HM) during the first 18 months of treatment but also among their partners. To identify information needs on sexuality, six questions were developed for this study. In addition to the results of Albers et al., we here report not only cross-sectional data but also longitudinal data of information needs on sexuality of patients and their partners as the need for information might well change over time. This prospective survey was conducted in the Netherlands between 2013 and 2015. Adult patients (n = 344) diagnosed with HM and their partners were invited to participate directly after diagnosis (T0), 3 months (T1), 6 months (T2), 1 year (T3), and 18 months after diagnosis (T4). With regard to sexuality, the Sexual and Fertility Information Needs Questionnaire (SFINFOQ) is comprised of 6 items on information needs regarding (1) changes in sexuality (3 items), (2) support for sexual difficulties (2 items), and (3) precautions that need to be taken (1 item). The response format of the items was a 5-point Likert scale (range: not important to extremely important). The responses “very important” and “extremely important”were identified as an informational need at that time. Furthermore, the survey included items on possible factors that might influence information needs. Except for age (categorized in clinically relevant blocks: adolescents and young adults < 36 years, adults 36–69 years, older adults ≥ 70 years), education (low, middle, and high), and diagnosis (per disease), all other sociodemographic and health status variables were dichotomized. A multivariable model was built with a forward selection procedure using generalized estimating equations, to account for the longitudinal data collection (p value for entry < 0.05). All data were analyzed using IBM SPSS 26 statistics. The study was approved by the Ethics Committee of the VU University Medical Center, Amsterdam, the Netherlands. Written informed consent was obtained from all patients. In total, the survey was completed by 266 patients and 134 partners at one or more time points. The mean age of the patients at time of diagnosis was 58 years (SD 14.9). Over 18 months from diagnosis, range 42 (at T0) to 48% (at T3) of patients expressed a need for information regarding changes in sexuality, 40 (T1) to 44% (T3) expressed a need for support for sexual difficulties, and 41 (T3) to 46% (T0) expressed a need for precautions that need to be taken. Multivariable analyses (Fig. 1) revealed that information needs of patients regarding changes in sexuality and precautions to be taken were associated with younger age, male sex, and a monitoring cognitive coping style. A need for support was associated with younger age and a monitoring coping style. Regarding their partners, 34% (T4) to 52% (T3) expressed a need for information regarding changes in sexuality, 39% * Corien M. Eeltink C.Eeltink@vumc.nl

Reply to: "Discussing sexuality in cancer care: towards personalized information for cancer patients and survivors".

/pdf/first-line-treatment-and-survival-of-newly-diagnosed-primary-nie9z1s1mg.pdf

First-line treatment and survival of newly diagnosed primary plasma cell leukemia patients in the Netherlands: a population-based study, 1989-2018

Risk of second primary malignancies in patients with follicular lymphoma: a population-based study in the Netherlands, 1989-2018

Supplemental Digital Content is available in the text

Otto Visser

Papers

Reply to: "Discussing sexuality in cancer care: towards personalized information for cancer patients and survivors".

First-line treatment and survival of newly diagnosed primary plasma cell leukemia patients in the Netherlands: a population-based study, 1989-2018

Risk of second primary malignancies in patients with follicular lymphoma: a population-based study in the Netherlands, 1989-2018

Treatment and Survival of Patients With Primary Effusion Lymphoma in the Netherlands: A Population-based Analysis, 2002-2015.

Treatment Utilization and Survival for Elderly Patients with Stage I Nsclc: A Population-Based Time-Trend Analysis